News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Initial Patient Enrolled in Phase 2a Clinical Trial of GFH009 for Acute Myeloid Leukemia, Announced by SELLAS
Friday, June 23, 2023SELLAS Life Sciences Group Inc NASDAQ SLS has recently commenced a Phase a clinical trial to evaluate the efficacy of its novel CDK inhibitor GFH in combination with venetoclax and azacitidine azaven for the treatment of relapsedrefractory acute myel...
Palleon Pharmaceuticals Initiates GLIMMER-01 Phase 1/2 Clinical Trial, Administering E-602 in Combination with Cemiplimab to First Patient
Friday, June 23, 2023Palleon Pharmaceuticals a clinicalstage company specializing in glycoimmunology drug development for the treatment of cancer and inflammatory diseases has announced the initiation of the combination therapy cohort of the Phase clinical trial for its...
Aptorum Group Shares Latest Progress on Clinical Trial for Neuroblastoma Using Repurposed Small Molecule Drug SACT-1: Phase 1b/2a Updates
Friday, June 23, 2023Aptorum Group Limited Nasdaq APM is a clinical stage biopharmaceutical company that focuses on developing novel technologies for the treatment of oncological diseases including neuroblastoma Recently Aptorum announced that it has submitted the Phase...
Cormedix Inc. Receives FDA Acceptance for Resubmitted New Drug Application for Defencath
Thursday, June 22, 2023CorMedix Inc listed on Nasdaq as CRMD is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for the treatment and prevention of lifethreatening diseases and conditions Recently the company announ...
Vascepa® (Icosapent Ethyl) by Amarin Granted Approval in the Kingdom of Saudi Arabia (KSA) to Decrease Cardiovascular Risk
Thursday, June 22, 2023Amarin Corporation plc NASDAQ AMRN and its commercialization partner Biologix FZco have jointly announced the approval of a new indication and label expansion for VASCEPA icosapent ethyl capsules by the Saudi Food and Drug Authority SFDA in the Kingd...
FDA Approves Argenx's VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis, Announced by Halozyme
Wednesday, June 21, 2023Halozyme Therapeutics Inc NASDAQ HALO has announced that argenx has received approval from the US Food and Drug Administration FDA for VYVGART Hytrulo efgartigimod alfa and hyaluronidaseqvfc injection with ENHANZE
Advantage Therapeutics Obtains Approvals for Clinical Trial of AD04™ in Treating Alzheimer's Disease in Poland, Bulgaria, and Slovakia
Wednesday, June 21, 2023ADvantage Therapeutics Inc has announced that regulatory authorities in Poland Bulgaria and Slovakia have granted approval for its Clinical Trial Application CTA to conduct a clinical trial on AD the companys lead candidate for the treatment of mild...
Curia Enhances Cell Line Development Services With the Innovative CHOZN Platform
Wednesday, June 21, 2023Curia a leading contract research development and manufacturing organization has recently entered into a licensing agreement with MilliporeSigma the North American Life Sciences Business of Merck KGaA Darmstadt Germany This agreement grants Curia and...
Argenx Granted FDA Approval for VYVGART Hytrulo (Efgartigimod Alfa and Hyaluronidase-qvfc) Injection in Generalized Myasthenia Gravis
Wednesday, June 21, 2023Argenx SE a global immunology company focused on enhancing the lives of individuals with severe autoimmune diseases has recently received approval from the US Food and Drug Administration FDA for VYVGART Hytrulo This newly approved medication is inte...
Genomic Vision and the Institute of Cancer Research, London Forge Technology Agreement Partnership
Tuesday, June 20, 2023Genomic Vision FR GV is a biotechnology company traded on Euronext that specializes in precise DNA sequence characterization They recently announced a partnership with The Institute of Cancer Research ICR in London The agreement involves the sale of...
